MedTrace Logo

Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults

NCT06669234 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2026-02-23

No results posted yet for this study

Summary

This clinical research trial will evaluate the safety and tolerability of an experimental drug, ALN-F1202, in healthy participants.

The purpose of this trial is to learn about how safe and tolerable the experimental drug is. The trial is looking at several other research questions, including:

* What side effects may happen from taking the experimental drug?
* How much experimental drug is in the blood at different times?
* Whether the body makes antibodies against the experimental drug (which could make the drug less effective or could lead to side effects).
* What is the best dose of the experimental drug?

Conditions

  • Healthy Volunteer

Interventions

DRUG

ALN-F1202

Administered per the protocol

DRUG

Matching Placebo

Administered per the protocol

Sponsors & Collaborators

Principal Investigators

  • Clinical Trial Management · Regeneron Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-06
Primary Completion
2026-07-30
Completion
2026-07-30
FDA Drug
Yes

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06669234 on ClinicalTrials.gov